Mycobacterial Immunology, IPH-Pasteur Institute Brussels, Brussels, Belgium.
PLoS Negl Trop Dis. 2008 Mar 19;2(3):e199. doi: 10.1371/journal.pntd.0000199.
Vaccination with plasmid DNA encoding Ag85A from M. bovis BCG can partially protect C57BL/6 mice against a subsequent footpad challenge with M. ulcerans. Unfortunately, this cross-reactive protection is insufficient to completely control the infection. Although genes encoding Ag85A from M. bovis BCG (identical to genes from M. tuberculosis) and from M. ulcerans are highly conserved, minor sequence differences exist, and use of the specific gene of M. ulcerans could possibly result in a more potent vaccine. Here we report on a comparison of immunogenicity and protective efficacy in C57BL/6 mice of Ag85A from M. tuberculosis and M. ulcerans, administered as a plasmid DNA vaccine, as a recombinant protein vaccine in adjuvant or as a combined DNA prime-protein boost vaccine. All three vaccination formulations induced cross-reactive humoral and cell-mediated immune responses, although species-specific Th1 type T cell epitopes could be identified in both the NH2-terminal region and the COOH-terminal region of the antigens. This partial species-specificity was reflected in a higher--albeit not sustained--protective efficacy of the M. ulcerans than of the M. tuberculosis vaccine, particularly when administered using the DNA prime-protein boost protocol.
用编码来自牛型结核分枝杆菌卡介苗的 Ag85A 的质粒 DNA 进行免疫接种,可以部分保护 C57BL/6 小鼠免受随后的溃疡分枝杆菌足部挑战。不幸的是,这种交叉反应性保护不足以完全控制感染。尽管编码来自牛型结核分枝杆菌卡介苗(与结核分枝杆菌基因相同)和溃疡分枝杆菌的 Ag85A 的基因高度保守,但存在微小的序列差异,并且使用溃疡分枝杆菌的特定基因可能会导致更有效的疫苗。在这里,我们报告了在 C57BL/6 小鼠中比较结核分枝杆菌和溃疡分枝杆菌的 Ag85A 的免疫原性和保护效力,Ag85A 作为质粒 DNA 疫苗、佐剂中的重组蛋白疫苗或 DNA 初免-蛋白加强疫苗进行给药。所有三种疫苗制剂均诱导了交叉反应性体液和细胞介导的免疫应答,尽管在抗原的 NH2 末端和 COOH 末端区域都可以鉴定出种特异性 Th1 型 T 细胞表位。这种部分种特异性反映在溃疡分枝杆菌疫苗比结核分枝杆菌疫苗具有更高(尽管不是持续)的保护效力,尤其是在使用 DNA 初免-蛋白加强方案给药时。